Nephrogenic fibrosing dermopathy: A novel cutaneous fibrosing disorder in patients with renal failure

American Journal of Medicine

Volumn 114, Issue 7, 2003, Pages 563-572

  Swartz, Richard D ^a,c   Crofford, Leslie J ^a   Phan, Sem H ^b   Ike, Robert W ^a   Su, Lyndon D ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ALPHA ACTIN; ATENOLOL; CARBAMAZEPINE; COLCHICINE; CYCLOSPORIN; CYTOKINE; DIGOXIN; ERYTHROPOIETIN; ESTROGEN; FUROSEMIDE; GABAPENTIN; GLIBENCLAMIDE; HISTOCOMPATIBILITY ANTIGEN; LISINOPRIL; MEGESTROL; METOCLOPRAMIDE; METOPROLOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PRAVASTATIN; PREDNISONE; SERTRALINE; TAMSULOSIN; THYROXINE; TRAZODONE; WARFARIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; EOSINOPHILIA MYALGIA SYNDROME; EOSINOPHILIC FASCIITIS; GRAFT REJECTION; HEMODIALYSIS; HEPATOBILIARY DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LABORATORY TEST; LIVER TRANSPLANTATION; MYOFIBROBLAST; MYXEDEMA; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROTOXICITY; PARAMETER; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK FACTOR; SCLEREDEMA; SCLERODERMA; SCLEROMYXEDEMA; SKIN BIOPSY; SKIN DISEASE; SKIN FIBROSIS; SMOOTH MUSCLE; SPAIN; SYSTEMIC SCLEROSIS; TISSUE INJURY; TISSUE REACTION; TOXIC OIL SYNDROME;

EID: 0037716844     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(03)00085-8     Document Type: Article

References (25)

1. Cowper S.E., Su L.D., Bhawan J., et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 23:2001;383-393.
2. Cowper S.E., Robin H.S., Steinberg S.M., et al. Scleromyxedema-like cutaneous diseases in renal-dialysis patients. Lancet. 356:2000;1000-1001.
3. Goveia M. CDC public health dispatch fibrosing skin condition among patients with renal disease - United States and Europe, 1997-2002 . MMWR Morb Mortal Wkly Rep. 51:2002;25-26.
4. Kohl M. Disease debut nephrogenic fibrosing dermopathy found in 49 patients with renal failure . Dermatol Times. 23:2002;1,31.
5. Weedon D. Cutaneous mucinoses. Weedon D. Skin Pathology. 1998;339-344 Churchill Livingston, London.
6. Leiferman K.M. Cutaneous eosinophilic diseases. Freedberg I.M., Eisen A.Z., Wolff K., et al. Dermatology in General Medicine. 1999;1129-1137 McGraw-Hill, New York.
7. Clauw D.J., Crofford L.J. Eosinophilic rheumatic disorders. Rheum Dis Clin North Am. 21:1995;231-246.
8. Webster G.F., Matsuoka L.Y., Burchmore D. The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol. 28:1993;105-108.
9. Godby A., Bergstresser P.R., Chaker B., Pandya A.G. Fatal scleromyxedema report of a case and review of the literature . J Am Acad Dermatol. 38:1998;289-294.
10. Leffell M.S., Steinberg A.G., Bias W.B., et al. The distribution of HLA antigens and phenotypes among donors and patients in the UNOS registry. Transplantation. 58:1994;1119-1130.
11. Rongioletti F., Rebora A. Updated classification of papular mucinosis, lichen myxedematosus and scleromyxedema. J Am Acad Dermatol. 44:2001;273-281.
12. Moulin V., Castilloux G., Auger F.A., et al. Modulated response to cytokines of human wound healing myofibroblasts compared to dermal fibroblasts. Exp Cell Res. 238:1998;283-293.
13. Clark R.A.F. Regulation of fibroplasia in cutaneous wound repair. Am J Med Sci. 306:1993;42-48.
14. Ehrlich H.P., Desmouliere A., Diegelmann R.F., et al. Morphological and immunochemical differences between keloid and hypertrophic scar. Am J Pathol. 145:1994;105-113.
15. Santucci M., Borgognoni L., Reali U.M., Gabbiani G. Keloids and hypertrophic scars of caucasians show distinctive morphologic and immunophenotypic profiles. Virchows Arch. 438:2001;457-463.
16. Kirk T.Z., Mark M.E., Chua C.C., et al. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem. 270:1995;3423-3428.
17. Kirk T.Z., Mayes M.D. Il-1 rescues scleroderma myofibroblasts from serum-starvation-induced cell death. Biochem Biophys Res Commun. 255:1999;129-132.
18. Phan S.H., Zhang K., Zhang H.Y., Gharaee-Kermani M. The myofibroblast as an inflammatory cell in pulmonary fibrosis. Curr Top Pathol. 93:1999;173-182.
19. Desmouliere A., Geinoz A., Gabbiani F., Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 122:1993;103-111.
20. Vyalov S., Desmouliere A., Gabbiani G. GM-CSF-induced granulation tissue formation relationships between macrophage and myofibroblast accumulation . Virchows Arch B Cell Pathol Mol Pathol. 63:1993;231-239.
21. Gharaee-Kermani M., Phan S.H. Role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr Pharm Des. 7:2001;1083-1103.
22. Desmouliere A., Badid C., Bochaton-Piallat M.L., Gabbiani G. Apoptosis during wound healing, fibrocontractive diseases and vascular wall injury. Int J Biochem Cell Biol. 29:1997;19-30.
23. Desmouliere A., Redard M., Darby I., Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol. 146:1995;56-66.
24. 1. Am J Respir Cell Mol Biol. 21:1999;658-665.
25. Navas-Palacios J.J., Conde-Zurita J.M. Inclusion body myofibroblasts other than those seen in recurring digital fibroma of childhood. Ultrastruct Pathol. 7:1984;109-121.